TransEnterix (TRXC) Misses Q1 EPS by 1c, Revenues Miss

TransEnterix (NYSE: TRXC) reported Q1 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $5.81 million.

• Total revenue of $2.2 million in the first quarter of 2019
• Sold one Senhance System globally in the first quarter in 2019
• Received U.S. FDA clearance for Senhance Ultrasonic System

“Commercially, we were disappointed with our results in the first quarter. We did however make solid progress towards the expansion of our global sales infrastructure and the development of our U.S. installed base to support future growth,” said Todd M. Pope, President and CEO of TransEnterix. “As we look to the balance of 2019, we will continue to leverage the commercial foundation we have built globally to drive the adoption of Senhance both in the U.S. and abroad. We remain confident in the quality of the global pipeline and expect to show meaningful revenue growth in the second half of the year.”

For earnings history and earnings-related data on TransEnterix (TRXC) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49